Stock Market News
Autolus pricing for Nasdaq IPO reveals gains for Syncona, Woodford, Arix
Autolus Therapeutics has confirmed the pricing for its initial public offer on the Nasdaq index of the New York Stock Exchange, providing a monetary boost for shareholders including Syncona, the Woodford Patient Capital fund and Arix Bioscience.
In the Securities and Exchange Commission registration statement for its IPO, Autolus gave an indicative pricing range for the proposed offering of $15-17 per American depositary shares, each of which will represent one ordinary share.
Autolus, which is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, proposed a maximum aggregate offering amount in the SEC filing of $125m.
For FTSE 250-listed Syncona, which owns 38% of Autolus, it would represent an increase in value of £49.5-67.7m or 7.4p-10.2p per Syncona share. Syncona also confirmed that it is interested in purchasing ADSs in the offering, subject to agreement with the underwriters.
Syncona noted that the proposed maximum aggregate offering of $125m assumes the offering price is at the midpoint of the indicative pricing range and does not include the underwriters' option to purchase additional ADSs.
For the Woodford fund, which owns a 20% stake of Autolus that makes up 4.35% of the trust's investments, the pricing would represent an increase in value of its current shareholding in Autolus of £25.9-35.1m or 3.1p-4.2p per WPCT share, compared its valuation in April.
Arix, for which Autolus is its largest shareholding, the IPO suggests a £10.5-14.6m increase in value from its £20.1m 2018 sterling holding value. Arix has also indicated an interest in purchasing ADSs in the offering.
In the Securities and Exchange Commission registration statement for its IPO, Autolus gave an indicative pricing range for the proposed offering of $15-17 per American depositary shares, each of which will represent one ordinary share.
Autolus, which is a biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, proposed a maximum aggregate offering amount in the SEC filing of $125m.
For FTSE 250-listed Syncona, which owns 38% of Autolus, it would represent an increase in value of £49.5-67.7m or 7.4p-10.2p per Syncona share. Syncona also confirmed that it is interested in purchasing ADSs in the offering, subject to agreement with the underwriters.
Syncona noted that the proposed maximum aggregate offering of $125m assumes the offering price is at the midpoint of the indicative pricing range and does not include the underwriters' option to purchase additional ADSs.
For the Woodford fund, which owns a 20% stake of Autolus that makes up 4.35% of the trust's investments, the pricing would represent an increase in value of its current shareholding in Autolus of £25.9-35.1m or 3.1p-4.2p per WPCT share, compared its valuation in April.
Arix, for which Autolus is its largest shareholding, the IPO suggests a £10.5-14.6m increase in value from its £20.1m 2018 sterling holding value. Arix has also indicated an interest in purchasing ADSs in the offering.
Related share prices |
---|
Syncona Limited NPV (SYNC) share price |
Woodford Patient Capital Trust (WPCT) share price |
Arix Bioscience (ARIX) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price